ARCHIVES

Pitt Criticizes NCI Stance On Repayment For Fraud Trials

This article is from The Cancer Letter archive.

Vol. 20 No. 34 | September 9, 1994

Download PDF Visit The Full Archive

Related Articles

Pertuzumab Delays Progression In HER2-Positive Breast Cancer

August 26, 2011

FDA Committee Approves NDA for Mitxantrone

March 21, 1986

Guidelines Proposed For Control Grants

January 25, 1980

In Brief: City of Hope Wins $5.5M Grant From NIA; Comis To Head Group Chairmen’s Committee

November 23, 1997

Gynecologic Oncology Group To Conduct Phase III Trial of Xyotax For Ovarian Cancer

April 30, 2004

Bioassay Backlog Reports show Increasing Number Of Equivocal Results; Is The Program A Failure?

September 2, 1977